Abstract:Abstract Use of α-androgenic receptor blockers remains a mainstay therapeutic approach for the treatment of urological diseases. Silodosin is recommended over other α-blockers for the treatment of lower urinary tract symptoms (LUTS) and benign prostate hyperplasia (BPH), due to its high α1A uroselectivity. Current research data suggest that silodosin is efficacious in the management of various urological diseases. Thus, we herein review the current evidence of silodosin related to its efficacy and tolerability and appraise the available literature that might ultimately aid in management of various urological conditions at routine clinical practice. Literature reveals that silodosin is beneficial in improving nocturia events related to LUTS/BPH. Silodosin exerts effect on relaxing muscles involved in detrusor obstruction, therefore prolonging the need for patients undergoing invasive surgery. Silodosin treatment, either as a monotherapy or combination, significantly improves International Prostate Symptom Score (IPSS) including both storage and voiding symptoms in patients with BPH/LUTS. Patients on other treatment therapies such as phosphodiesterase 5 inhibitors or other α-blockers are well managed with this drug. Steadily, silodosin has proved beneficial in the treatment of other urological disorders such as chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), overactive bladder/acute urinary retention (AUR), premature ejaculation (PE), and prostate cancer post brachytherapy-induced progression. In patients with distal ureteral stones, silodosin treatment is beneficial in decreasing stone expulsion time without affecting stone expulsion rate or analgesic need. Moreover, there were significant improvements in intravaginal ejaculation latency time, quality of life scores, and decrease in PE profile among patients with PE. Silodosin has also demonstrated promising results in increasing the likelihood of successful trial without catheter in patients with AUR and those taking antihypertensive drugs. Reports from Phase II studies have shown promising role of silodosin in the treatment of CP/CPPS as well as facilitating ureteral stone passage. From the robust data in this review, further silodosin treatment strategies in the management of different urological conditions need to be focused on.

The Influence of UGT2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Silodosin in Healthy Chinese Volunteers

Differences in Cyp3a4*1g Genotype Distribution and Haplotypes of Cyp3a4, Cyp3a5 and Cyp3a7 in 3 Chinese Populations

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

ABCB1 Haplotype Influences the Sirolimus Dose Requirements in Chinese Renal Transplant Recipients.

Safety and Pharmacokinetic Studies of Silodosin, a New .Alpha.1a-Adrenoceptor Selective Antagonist, in Healthy Chinese Male Subjects

The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.

Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review

Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients

Simvastatin Pharmacokinetics in Healthy Chinese Subjects and Its Relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 Polymorphisms.

Frequency of CYP2D610 and 14 Alleles and Their Influence on the Metabolic Activity of CYP2D6 in a Healthy Chinese Population

The Influence of MDR1 G2677T/A Genetic Polymorphisms on the Pharmacokinetics of Repaglinide in Healthy Chinese Volunteers

Systematic Screening for Polymorphisms in the CYP3A4 Gene in the Chinese Population.

Genetic Polymorphisms in Mdr1 and Cyp3a5 and Mdr1 Haplotype in Mainland Chinese Han, Uygur and Kazakh Ethnic Groups

Identification and Functional Assessment of Eight CYP3A4 Allelic Variants 39-46 Detected in the Chinese Han Population

CYP2C19 681G > A Polymorphism and Pharmacokinetics of Clopidogrel in Chinese Healthy Volunteers.

Understanding the side effects of chronic silodosin administration via untargeted metabolomics approach

A Randomized Study on the Bioequivalence of Desloratadine in Healthy Chinese Subjects and the Association of Different Metabolic Phenotypes With UGT2B10 and CYP2C8 Genotypes

The Influence of CYP3A5*3 and BCRPC421A Genetic Polymorphisms on the Pharmacokinetics of Felodipine in Healthy Chinese Volunteers.

Effect of Cyp1a2 Polymorphism on the Pharmacokinetics of Agomelatine in Chinese Healthy Male Volunteers

Effects of UGT1A1, CYP3A5 and ABCB1 Genetic Variants on Pharmacokinetics of Antihistamine Drug Mizolastine in Chinese Healthy Volunteers

Impact of the CYP2D6 Genotype on Metoprolol Tolerance and Adverse Events in Elderly Chinese Patients With Cardiovascular Diseases